An excerpt of an international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease （2023）
- VernacularTitle:《2023年国际多学科专家共识： 代谢相关脂肪性肝病和慢性肾脏病风险》摘译
- Author:
Danqin SUN
1
;
Jiaqi SHEN
1
;
Minghua ZHENG
2
Author Information
- Publication Type:Journal Article
- Keywords: Metabolic Associated Fatty Liver Disease; Non-Alcoholic Fatty Liver Disease; Kidney Disease; Consensus
- From: Journal of Clinical Hepatology 2024;40(1):42-45
- CountryChina
- Language:Chinese
- Abstract: In 2020， an international expert panel proposed to replace nonalcoholic fatty liver disease with metabolic associated fatty liver disease （MAFLD）. Recent studies have shown that there is a higher risk of chronic kidney disease （CKD） in the MAFLD population and that MAFLD is an independent risk factor for CKD. However， up to now， there are still no guidelines on the prevention and treatment of MAFLD-related CKD. Based on the Delphi method， the authors led a multidisciplinary team of 50 authoritative experts from 26 countries to reach a consensus on some open-ended research issues about the association between MAFLD and CKD， which can help to clarify the important clinical association between MAFLD and the risk of CKD and improve the understanding of the epidemiology， pathogenesis， management， and treatment of MAFLD and CKD， so as to establish a framework for the early prevention and management of these two common and interrelated diseases.
